Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I expect there is no institutional ownership in Ariad based on Rida. So, if Rida is not approved, there may be a swift move downward in the share price in the short term, however, the institutional investors will stay the course..
aria2010, couldn't agree with you more..
Duplicate post removed
Rumors of a Jeffries upgrade as well, but I do not have details
Wow, I do not like this action in the market.. And, Ariad broke trend..
I don't know guys, look at the chart above.. ^ ..lower lows and lower highs over the last 30 days.. I thought that was negative..
What he actually said was we will see '113 data in the second half of 2012..
Yes, 10X more potent in the petri dish and mouse models. We will know so, so much more by the end of this year from the clinicals. And, Harvey gave us some real valuable information yesterday on the call..
I tell you, Harvey Berger is absolutely at the top of his game.. Really. If you listen to the analysts that called into the CC, he was educating about 50% of them on how the EU and FDA regulatory processes work..
Rachel McMinn is absolutely clueless as a research analyst and has missed the entire 140% move up in Ariad over the last year, and is still neutral. Her client(s) are going to miss the next $10 in share price appreciation of Ariad as well. When she is finally in, I'm out.. disgusting.. All imho, of course...
Swing of one dollar today.... fwiw...
I agree. I love Harvey's closing remark, where on the next update, how Ariad will be delivering "flawless execution"
That's easy. The ramp up in sales of Pona in 2013 and 2014 will not offset the cash burn rate in 2014. They will do the 10MM share offering in the middle of 2013, hopefully in the mid twenties.. That should get them to the promised land..
The '113 information IS the game changer..
Wow, they will burn through $140 million in 2012 (mostly R&D), and have left $160 million at the end of 2012 (out of the $306 million they had at the end of 2011). That will take them through 2013, and that's it..
As Steven Roach of M.S. said recently, The Chinese economy create the equivalent annual GDP of Greece in about 12 weeks.. oil is much more important.
That said, the talking heads say that any conflict with Iran would be brief. I still say if it does happen, the fifth fleet will play a role..
There were 2 or 3 SEC filings tonight.
Sweet.. Maria Cantor is now a SVP.
Frank "me boy" Haluska is not a big share holder as I thought, but it might be due that possibly he is on his second or third marriage..
Now, this is à pig..
Rolled right through the 30 day, and is heading to the 50 day.. unfortunately ... Risk OFF after "saving Greece", LOL..
When it's down $1.00 in two days (friday $.60, and $.40 a few minutes ago), it grabs my attention..
And, the chart is ugly..
Freaking ouch..
The most important thing is that 80% of options expire worthless, so I've always sold options to take advantage of that. Once in a while, I'll buy them. I'm sure that those here on the Ariad board are much more astute in purchasing Ariad CALLS than the average trader (When the stock is up 140% in one year, that doesn't hurt either.. LOL)
Negative.
That is not a "small" old house.. look again..
At Ariad's Leerink Swann Global Healthcare Conference yesterday, somewhere between the 3rd minute and the 12th minute (wide berth, I know) of the Ariad presentation, Dr. Havey Berger mentioned that we will hear some PR on Ponatinib's application with AML and solid tumors in 2012..
Slide 36, unaudited Financial Summary:
Bio CEO & Investor Conference
02.13.2012
Unaudited
Financial Summary 2011
(dollars in millions)
Cash and cash equivalents – Dec 31, 2011
$306 million
Cash used in operations – 2011
$53 million
Look at the slides from the presentation on Feb 13th. End of 2011, they have $306 million.
Ariad wins key patent on Ponatinib, hires 40 people since January, plans to hire 100 more
http://bostonglobe.com/business/2012/02/15/ariad-pharmaceuticals-wins-key-patent-drug-treat-chronic-myeloid-leukemia/fCin3qwde6moiUm6xSTApM/story.html
Ariad wins key patent for Pona, hires 40 people since January 1st, will hire 100 more..
http://bostonglobe.com/business/2012/02/15/ariad-pharmaceuticals-wins-key-patent-drug-treat-chronic-myeloid-leukemia/fCin3qwde6moiUm6xSTApM/story.html
Fmr (Fidelity) now owns 14.63%, or 23,051,879 shares.
You may want to look at Rodman& Renshaw's recent spreadsheet (posted in an earlier message)on their modeling of revenue and profit margin for Ariad (and they do model '113). Rida's royalities are minimal..